Best Drug Manufacturers - General Stocks for 2026
Big pharma earns premium gross margins on branded pipelines and annuity-like franchises; Health-pillar cash coverage against patent cliffs matters as much as Quality.
General Drug Manufacturers (big pharma) earn premium gross margins on branded pipelines plus annuity-like revenue from in-line franchises. Composite scoring weights the Quality pillar (gross margin, ROIC, FCF conversion) and the Health pillar (patent-cliff cash coverage); Growth pillar uses pipeline NPV proxies.
Data as of (updated daily)
Top 20 Drug Manufacturers - General stocks by composite score
| # | Ticker | Name | Composite |
|---|---|---|---|
| 1 | 300181.SHE | Zhejiang Jolly Pharmaceutical Co Ltd | 71.3 |
| 2 | 001367.SHE | Zhejiang Haisen Pharmaceutical Co. Ltd. A | 69.3 |
| 3 | NOV.XETRA | NOVO-NORDISK AS B DK 0,1 | 68.9 |
| 4 | 300357.SHE | Zhejiang Wolwo Bio-Pharmaceutical Co Ltd | 68.7 |
| 5 | GRFS.US | Grifols SA ADR | 65.8 |
| 6 | 000411.SHE | Zhejiang Int'L Group Co Ltd | 65.3 |
| 7 | 1093.HK | CSPC Pharmaceutical Group Ltd | 65.1 |
| 8 | LLY.US | Eli Lilly and Company | 64.4 |
| 9 | AMGN.BA | Amgen Inc. | 63.3 |
| 10 | BMY.US | Bristol-Myers Squibb Company | 62.0 |
| 11 | LLY.XETRA | Eli Lilly and Company | 61.7 |
| 12 | VIRP.PA | Virbac SA | 61.5 |
| 13 | PNVL3.SA | Dimed S.A. Distribuidora de Medicamentos | 60.1 |
| 14 | AMG.XETRA | Amgen Inc. | 60.0 |
| 15 | LLY.MX | Eli Lilly and Company | 59.9 |
| 16 | MARKSANS.NSE | Marksans Pharma Limited | 59.3 |
| 17 | BRM.XETRA | Bristol-Myers Squibb Company | 59.0 |
| 18 | LILY34.SA | Eli Lilly and Company | 59.0 |
| 19 | 002422.SHE | Sichuan Kelun Pharmaceutical Co Ltd | 58.3 |
| 20 | NOVO.TO | Novo Nordisk CDR (CAD Hedged) | 58.3 |
Want to drill into Drug Manufacturers - General stocks?
The full screener applies the Drug Manufacturers - General industry filter and lets you stack 30+ more filters on top: market cap, country, dividend yield, and the four pillar scores.
Open in screener →Explore related pages
Drug Manufacturers - General by strategy
Drug Manufacturers - General by country
Other industries in Healthcare
Parent sector
Recent Drug Manufacturers - General insights
- Analysis
GSK Analysis: 28.3% ROE and 13.01 P/E Signal Deep Value Opportunity
$GSK delivers an elite 28.3% ROE, generating nearly 30 cents of profit per dollar of shareholder equity.
- Analysis
Costamare (CMRE) Q3: Adjusted EPS $0.81, P/E 4.61x, P/B 0.74x
CMRE posts a P/E of 4.61, P/B 0.74 and ROE 14.72% after Q3 2025 adjusted net income of $98M ($0.81/share), yielding a Valuation Score of 85/100.
- Analysis
NVIDIA $4.58T Market Cap, FY25 Revenue $130.5B, ROE 109.42%, P/E 57.64x
NVIDIA leads the group with a $4.58T market cap and an exceptional 109.42% ROE while reporting FY25 revenue of $130.5B (up 114%) and a P/E of 57.64.
- Sector Spotlight
Healthcare Sector Averages 51/100 Score, 31.2x P/E, -17.6% ROE
Healthcare sector averages 51/100 score, P/E 31.2, and -17.6% ROE, signaling broad profitability issues despite premium valuations.
- Sector Spotlight
Healthcare Averages 31.2x Earnings, NUTX at 2.38x, GSK 13.01x
Healthcare sector averages 52/100 valuation score with P/E of 31.2, trading 50% above S&P 500 norms, yet quality leaders like NUTX (P/E 2.38) and GSK (P/E 13.01) offer deep discounts.
Methodology: How we score stocks. Data refreshed nightly around 03:30 ET. This page lists the top 20 by composite score; use the screener for the full ranked list.